Phase 2Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])
- Sponsor
- Avalyn Pharma Inc. (Industry)
- Enrolment
- 340 planned
- Conditions
- Progressive Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- AP01
- Ages
- adults, older adults
- Registry
- NCT06951217
Full record on ClinicalTrials.gov
From the registry
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.
Primary outcomes
- To evaluate the long-term safety and tolerability outcomes of subjects receiving Avalyn nebulized antifibrotic medications (AP01).
History
Primary completion expected
Last registry update
Registered
Started